Wood 2002

Methods	Computer‐generated random number list in blocks. Pharmacy prepared numbered envelopes. Tablets not identical so placed by nurse in opaque vaginal introducer for physician to insert ‐ to maintain allocation concealment.
Participants	50 women with ultrasound diagnosed non‐viable pregnancies. Gestational age 7‐17 weeks but women not included if fetal size by ultrasound > 12 weeks equivalent. Also excluded from recruitment if experiencing uterine cramping or bleeding.
Interventions	Misoprostol (800 mcg vaginally) (n = 25) or vaginal placebo (n = 25). If complete miscarriage not suspected after 24 hours, treatment was repeated. At 48 hours, if no miscarriage or miscarriage thought to be incomplete, uterine curettage was offered.
Outcomes	Sample size based on reduction of uterine curettage from 50% to 10%. Women's satisfaction also assessed, but are not included in analyses as data not reported from control group.
Notes	Analysis by intention to treat.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐ Adequate

ERPC: evacuation of retained products of conception hCG: human chorionic gonadotropin IM: intramuscular IU: international units mcg: microgrammes MTX: methotrexate POCs: products of conception TVS: transvaginal sonography vs: versus